ES2033850T5 - Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas. - Google Patents

Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.

Info

Publication number
ES2033850T5
ES2033850T5 ES87306174T ES87306174T ES2033850T5 ES 2033850 T5 ES2033850 T5 ES 2033850T5 ES 87306174 T ES87306174 T ES 87306174T ES 87306174 T ES87306174 T ES 87306174T ES 2033850 T5 ES2033850 T5 ES 2033850T5
Authority
ES
Spain
Prior art keywords
days
dosage form
combination
treatment
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87306174T
Other languages
English (en)
Other versions
ES2033850T3 (es
Inventor
Gertrude Virginia Upton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2033850(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2033850T3 publication Critical patent/ES2033850T3/es
Publication of ES2033850T5 publication Critical patent/ES2033850T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE DESCRIBE AQUI UN METODO PARA APLICAR UNA TERAPIA DE SUSTITUCION HORMONAL Y UN ANTICONCEPTIVO A UNA MUJER PREMENOPAUSICA, QUE COMPRENDE ADMINSTRAR A UNA MUJER PREMENOPAUSICA QUE LA NECESITA UNA FORMA DE DOSIFICACION COMBINADA DE UN ESTROGENO SELECCIONADO DE ENTRE 0,5-2,0 MG DE 17 BETA-ESTRADIOL, 0,008-0,030 MG DE ETINIL ESTRADIOL Y 0,015-0,060 MG DE MESTRANOL; Y UN PROGETOGENO SELECIONADO DE ENTRE 0,025-0,100 MG DE LEVONORGESTREL, 0,010-0, 070 MG DE GESTODENE, 0,025-0,100 MG DE DESOGESTREL 0,025-0,100 MG DE 3-CETODESOGESTREL Y 0,085-0,35 MG DE NORETINDRONA, ADMINISTRANDOSE DICHA FORMA DE DOSIFICACION COMBINADA DURANTE 23-25 DIAS Y EMPEZANDO EN EL PRIMER DIA DEL CICLO MENSTRUAL, SEGUIDA POR 2 A 5 DIAS SIN PILDORAS O CON PILDORAS PLACEBO DURANTE UN TOTAL DE 28 DIAS DEL CICLO DE ADMINSTRACION. LA FORMA DE DOSIFICACION PREFERIDA DE LA INVENCION ES UNA COMBINACION DE 1 MG DE 17BETA-ESTRADIOL Y 0,050 O 0,075 MG DE LEVONORGESTREL. EL CICLO DE ADMINISTRACION PREFERIDO DE LA INVENCION ES LA ADMINISTRACION DE LA FORMA DE DOSIFICACION COMBINADA DURANTE LOS PRIMEROS 24 DIAS DEL CICLO MENSTRUAL Y NINGUNA FORMA DE DOSIFICACION DURANTE LOS ULTIMOS 4 DIAS DEL CICLO MENSTRUAL.
ES87306174T 1986-07-15 1987-07-13 Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas. Expired - Lifetime ES2033850T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88597186A 1986-07-15 1986-07-15

Publications (2)

Publication Number Publication Date
ES2033850T3 ES2033850T3 (es) 1993-04-01
ES2033850T5 true ES2033850T5 (es) 2001-07-01

Family

ID=25388101

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87306174T Expired - Lifetime ES2033850T5 (es) 1986-07-15 1987-07-13 Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.

Country Status (20)

Country Link
EP (1) EP0253607B2 (es)
JP (1) JP2645510B2 (es)
KR (1) KR960001371B1 (es)
AT (1) ATE75401T1 (es)
AU (1) AU597084B2 (es)
CY (1) CY1725A (es)
DE (1) DE3778599D1 (es)
DK (2) DK174724B1 (es)
ES (1) ES2033850T5 (es)
GB (1) GB2192542B (es)
GR (1) GR3004472T3 (es)
HK (1) HK67393A (es)
IE (1) IE61236B1 (es)
LU (1) LU90634I2 (es)
NL (1) NL300025I2 (es)
PH (1) PH25944A (es)
PT (1) PT85305B (es)
SG (1) SG55093G (es)
WO (1) WO1988000469A1 (es)
ZA (1) ZA875010B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE3864210D1 (de) * 1987-07-06 1991-09-19 Akzo Nv Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
ES2169030T3 (es) * 1987-09-24 2002-07-01 Jencap Res Ltd Envases de anticonceptivos que contienen estrogeno y progestina.
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
ATE271386T1 (de) * 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JP2001513566A (ja) * 1997-08-27 2001-09-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 経口避妊における、エストロゲンと子宮内膜節約性プロゲスチンおよび子宮内膜萎縮性プロゲスチンとの組み合わせ物
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
WO2003049744A1 (en) 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
CN101001631B (zh) 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
WO2005049142A2 (en) * 2003-11-14 2005-06-02 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20060135496A1 (en) 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007076144A2 (en) 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
TW200840595A (en) * 2006-12-12 2008-10-16 Organon Nv Oral contraceptive spray
ES2531929T3 (es) * 2006-12-20 2015-03-20 Teva Women's Health, Inc. Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
WO2009082478A1 (en) 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
ES2795455T3 (es) 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
US20180125860A1 (en) * 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669502A (en) 1971-01-05 1972-06-13 Simpson Timber Co Pneumatic spreader stoker
US3836651A (en) * 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
DE2310963A1 (de) 1972-04-14 1974-09-05 Schering Ag Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
ZA87332B (en) 1986-02-27 1987-08-26 Warner Lambert Co Compositions containing fixed combinations

Also Published As

Publication number Publication date
KR880701553A (ko) 1988-11-03
ZA875010B (en) 1989-02-22
DK351887A (da) 1988-01-16
GR3004472T3 (es) 1993-03-31
JPH01500431A (ja) 1989-02-16
EP0253607B2 (en) 2001-05-23
WO1988000469A1 (en) 1988-01-28
PT85305B (pt) 1990-03-30
ATE75401T1 (de) 1992-05-15
GB8716431D0 (en) 1987-08-19
LU90634I2 (fr) 2000-12-15
GB2192542A (en) 1988-01-20
AU597084B2 (en) 1990-05-24
AU7537987A (en) 1988-01-21
PH25944A (en) 1991-12-19
KR960001371B1 (ko) 1996-01-26
PT85305A (en) 1987-08-01
DK174724B1 (da) 2003-10-06
NL300025I1 (nl) 2001-01-02
CY1725A (en) 1994-05-06
HK67393A (en) 1993-07-23
IE871833L (en) 1988-01-15
JP2645510B2 (ja) 1997-08-25
DK351887D0 (da) 1987-07-08
DE3778599D1 (de) 1992-06-04
GB2192542B (en) 1990-05-02
NL300025I2 (nl) 2004-08-02
SG55093G (en) 1993-07-09
IE61236B1 (en) 1994-10-19
EP0253607A1 (en) 1988-01-20
ES2033850T3 (es) 1993-04-01
EP0253607B1 (en) 1992-04-29
DK365887D0 (da) 1987-07-14

Similar Documents

Publication Publication Date Title
ES2033850T5 (es) Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.
EP0717626B1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
PT911029E (pt) Contraceptivos orais em doses ultra-baixas com menos hemorragias menstruais e com eficacia prolongada
US3639600A (en) Process of establishing cyclicity in a human female
RU96115196A (ru) Состав для контрацепции
JPH04290830A (ja) 避妊薬処方物
CA2179728A1 (en) Composition for a contraceptive comprising an estrogen and a gestagen
JP2000502108A (ja) ゲストゲンとエストロゲン併用によるほ乳動物の避妊法とキット
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
JP2942560B2 (ja) エストロゲン欠乏症治療用組成物
CA2311937A1 (en) Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
CA2171460C (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
Vasilev Triphasic hormonal contraceptives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 253607

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: GESTODENO + ETINILESTRADIOL (MENESSE)

Spc suppl protection certif: C200000027

Filing date: 20001110

SPCG Supplementary protection certificate granted

Free format text: GESTODENO + ETINILESTRADIOL (MENESSE)

Spc suppl protection certif: C200000027

Filing date: 20001110

Expiry date: 20120713

Effective date: 20031008